of gastrointestinal neuroendocrine tumors, SSTR2 expression was 100% in tumors of early stage while only 56% of advanced stage tumors expressed SSTR2 (39). Here, SSTR2 is linked to digestive system neuroendocrine tumor, grade 1/2.